Aberrant activation, nuclear localization, and phosphorylation of yes-associated protein-1 in the embryonic kidney and Wilms tumor

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 198-205

  Murphy, Andrew J ^a   Pierce, Janene ^a   De Caestecker, Christian ^a   Libes, Jaime ^a   Neblett, David ^a   de Caestecker, Mark ^a   Perantoni, Alan O ^b   Tanigawa, Shunsuke ^b   Anderson, James R ^c   Dome, Jeffrey S ^d   Das, Amrita ^e   Carroll, Thomas J ^e   Lovvorn, Harold N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anaplasia; Biomarker; Nephrogenic rests; Wilms tumor; YAP1

Indexed keywords

PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY DEVELOPMENT; KIDNEY TUMOR; MALE; MOUSE; NEPHROBLASTOMA; NEPHRON; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT FAILURE; WESTERN BLOTTING;

EID: 84890863499     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24788     Document Type: Article

References (32)

1. Kalapurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: Current practice and future goals. Lancet Oncol 2004; 5:37-46.
2. Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21:357-364.
3. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28:2625-2634.
4. Dome JS, Fernandez CV, Mullen EA, et al. Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatr Blood Cancer 2013; 60:994-1000.
5. Huang CC, Gadd S, Breslow N, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 2009; 15:1770-1778.
6. Gadd S, Huff V, Huang CC, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: A Children's Oncology Group Study. Neoplasia 2012; 14:742-756.
7. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7:91-97.
8. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor-New definitions with prognostic significance: A report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996; 20:909-920.
9. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study. J Clin Oncol 2006; 24:2352-2358.
10. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-111.
11. Borovski T, De Sousa EMF, Vermeulen L, et al. Cancer stem cell niche: The place to be. Cancer Res 2011; 71:634-639.
12. Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150:780-791.
13. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13:877-883.
14. Hong W, Guan KL. The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23:785-793.
15. Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochim Biophys acta 2013; 1830:2323-2334.
16. Rosenbluh J, Nijhawan D, Cox AG, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151:1457-1473.
17. Li Y, Hibbs MA, Gard AL, et al. Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and hippo pathway effectors by Notch1. Stem cells 2012; 30:741-752.
18. Konsavage WM, Jr., Kyler SL, Rennoll SA, et al. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem 2012; 287:11730-11739.
19. Aragon E, Goerner N, Zaromytidou AI, et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 2011; 25:1275-1288.
20. Barry ER, Morikawa T, Butler BL, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013; 493:106-110.
21. Kang W, Tong JH, Chan AW, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 2011; 17:2130-2139.
22. Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32:389-398.
23. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-4585.
24. Katoh M. Function and cancer genomics of FAT family genes (review). Int J Oncol 2012; 41:1913-1918.
25. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24:72-85.
26. Reginensi A, Scott RP, Gregorieff A, et al. Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet 2013; 9:e1003380.
27. Saburi S, Hester I, Fischer E, et al. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nat Genet 2008; 40:1010-1015.
28. Alami J, Williams BR, Yeger H. erivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer 2003; 107:365-374.
29. Lovvorn HN, Westrup J, Opperman S, et al. CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia 2007; 9:589-600.
30. Murphy AJ, Pierce J, de Caestecker C, et al. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. J Pediatr Surg 2012; 47:1239-1249.
31. Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012; 44:133-139.
32. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44:570-574.